Qilu Pharmaceutical launches Phase I clinical trials of a new lipid-lowering drug targeting PCSK9 siRNA
On February 27, 2026, according to the website for clinical trials in the United States, the first phase of clinical trials for QLC7401 (RBD7022), a new small nucleic acid drug introduced by Qilu Pharmaceutical, was officially launched. This is a key progress in the domestic lipid-lowering siRNA therapy targeting PCSK9, bringing new treatment options for patients with hyperlipidemia. The trial number is NCT07441317, sponsored by Qilu Pharmaceutical.
Semaglutide Powder CAS 910463-68-2
1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-008
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Semaglutide Powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
It will evaluate the efficacy and safety of QLC7401 combined with lipid-lowering drugs at a subcutaneous injection dose of 100mg in the treatment of primary or mixed hyperlipidemia with elevated low-density lipoprotein cholesterol (LDL-C). Currently, the trial has not yet started subject recruitment. The original drug RBD7022 of QLC7401 was developed by Ruibo Biotechnology. It is a GalINAc conjugated siRNA drug based on its independently innovated RIBO GalSTAR @ liver targeted delivery technology. By targeting and inhibiting the key protein PCSK9 of lipid metabolism, it enhances the clearance ability of liver cells towards LDL-C and achieves precise and long-lasting lipid-lowering. In December 2023, Ruibo Biotechnology authorized the rights of the drug in mainland China, Hong Kong, and Macau to Qilu Pharmaceutical. With the complementary advantages of technology and industrialization, the two sides have promoted the rapid entry of the drug into a critical clinical stage.
Minwei Biotechnology's siRNA new drug has been approved for clinical trials by the National Medical Products Administration for use in primary hypertension
On March 1, 2026, Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Minwei Biotechnology") received approval from the National Medical Products Administration (hereinafter referred to as "NMPA") to issue a "Drug Clinical Trial Approval Notice" for MWX401 injection, with the indication of primary hypertension.
MWX401 injection is a small interfering RNA (siRNA) drug independently developed by Shanghai Minwei Biotechnology, with global intellectual property rights. It submitted a clinical trial application to CDE in December 2025, with indications for primary hypertension. Non clinical research results have shown that MWX401 can significantly reduce serum target protein, mRNA levels, systolic and diastolic blood pressure in induced hypertension humanized mice; In spontaneously hypertensive rhesus monkeys, single subcutaneous administration of different doses of MWX401 injection can significantly reduce animal AGT levels, as well as significantly lower systolic and diastolic blood pressure, with a good star effect relationship, superior to the positive control valsartan. The decrease in blood pressure can be maintained until the end of the experiment, and the drug effect in animals lasts for at least 12 weeks. Meanwhile, safety evaluation tests have shown that MWX401 has good safety.
The first subject to receive administration of the dual target siRNA drug BEBT-701 was successfully administered
On March 2, 2026, Bebret Pharmaceuticals announced today that the company's independently developed global first AGT/PCSK9 dual target small interfering RNA (siRNA) drug BEBT-701 has completed its first subject administration (First Patient In, FPI) at Xiangya Third Hospital of Central South University, marking the official entry of the project into clinical trials.
On February 2, 2026, BEBT-701 obtained the "Drug Clinical Trial Approval Notice" (No. 2026LP00318) approved and issued by the National Medical Products Administration (NMPA), and was granted permission to conduct phase 1-1 clinical trials for the treatment of mild to moderate hypertension with elevated low-density lipoprotein cholesterol (LDL-C). The project team completed the first subject enrollment within one month after approval, marking the full launch and rapid progress of the BEBT-701 clinical study as planned. Subsequent studies will systematically evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics, as well as the impact on blood pressure and lipid related indicators of this product, providing scientific basis for the design and implementation of key clinical studies in the future.
Novo Nordisk invests over 400 million euros to expand GLP-1 therapy production base
On March 2, 2026, Novo Nordisk announced an investment of 432 million euros (approximately 3.2 billion Danish kroner) to expand its production base in Ireland, which will significantly enhance Novo Nordisk's existing and future GLP-1 therapy production capacity.
It is reported that the entire project covers an area of 45 acres (18 hectares) and will create up to 500 construction jobs. The construction project has been initiated and will be gradually completed between the end of 2027 and 2028. The Novo Nordisk press release states that this investment is an important strategic milestone in the company's development journey, further consolidating Novo Nordisk's long-term commitment to healthcare innovation in Ireland and globally. It will provide Novo Nordisk with additional production capacity for oral products, enhance supply, and make Ireland an important hub for serving markets outside the United States. This investment will be used for the upgrade and renovation of existing facilities, as well as to enhance the production capacity of Novo Nordisk's oral GLP-1 therapy.
Peptide Biotech has completed over 500 million yuan in Series C financing, and the world's first GLP-1 monthly formulation has entered Phase III
On March 2, 2026, Beijing Zhipeptide Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as Zhipeptide Biotech) is a nearly commercialized biotechnology company focused on developing innovative drugs for chronic metabolic diseases. Recently, Peptide Biotech announced the completion of over 500 million yuan in Series C financing. This round of financing is led by Aobo Capital (0rbiMed), with Qiming Venture Capital, well-known industry funds, Wuyuan Capital, Xingze Capital, and Huagai Capital following suit. Old shareholders Taifu Capital, Lanchi Venture Capital, and Taiyu Investment continue to increase their investment, and Haoyue Capital serves as the exclusive financial advisor for this round of financing.
Peptide Biotech has developed differentiated ultra long acting, oral peptides, and multi-target layouts in the field of chronic metabolic diseases to meet the clinical needs of different patients. Innovative technology cross fusion will also lead the future trend of chronic metabolic disease treatment. Its core product, the innovative GLP-1 RA monthly formulation Zovigliptin (ZT002) Injection, is undergoing weight loss phase clinical trials (HORIZON-1 study) in China and is expected to become the world's first GLP-1 peptide to be administered once a month. Previously, Zovigliptin had demonstrated competitive efficacy and tolerability in phase I clinical trials, with a weight loss of up to 13.8% at week 24, and no plateau phase observed. The discontinuation rate due to gastrointestinal adverse events was almost zero.
According to CIC, the GLP-1 RA monthly formulation is expected to switch the weight loss treatment mode from weekly administration to monthly administration, greatly improving patient compliance. It is expected to account for about 26% of the global GLP-1 drug market worth $209.5 billion by 2035.
In addition, the company's oral peptide GLP-1 receptor agonist ZT006 tablet has launched Phase I clinical trials for weight loss in China; The dual target new product ZT003 injection (GLP-1/FGF21) is undergoing early morning clinical trials in Australia. Smeaglutide biological analog ZT001 has reached cooperation with Tonghua Dongbao and Aimeike respectively to promote the clinical development and commercialization of diabetes and weight loss indications simultaneously.
